Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Tracy Todd Batchelor, M.D.

Co-Author

This page shows the publications co-authored by Tracy Batchelor and William Curry.
Connection Strength

1.628
  1. Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma. JCO Precis Oncol. 2020; 4.
    View in: PubMed
    Score: 0.229
  2. Performance of a Hospital Pathway for Patients With a New Single Brain Mass. J Oncol Pract. 2019 Mar; 15(3):e211-e218.
    View in: PubMed
    Score: 0.208
  3. Impact of histopathological transformation and overall survival in patients with progressive anaplastic glioma. J Clin Neurosci. 2016 Sep; 31:99-105.
    View in: PubMed
    Score: 0.173
  4. Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma. Clin Cancer Res. 2016 06 15; 22(12):2885-96.
    View in: PubMed
    Score: 0.170
  5. Decreased rate of infection in glioblastoma patients with allelic loss of chromosome 10q. J Neurooncol. 2009 May; 93(1):115-20.
    View in: PubMed
    Score: 0.106
  6. A Rapid Genotyping Panel for Detection of Primary Central Nervous System Lymphoma. Blood. 2021 Mar 18.
    View in: PubMed
    Score: 0.060
  7. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell. 2019 08 08; 178(4):835-849.e21.
    View in: PubMed
    Score: 0.054
  8. Long-term outcomes and late adverse effects of a prospective study on proton radiotherapy for patients with low-grade glioma. Radiother Oncol. 2019 08; 137:95-101.
    View in: PubMed
    Score: 0.053
  9. PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. Clin Cancer Res. 2019 07 15; 25(14):4375-4387.
    View in: PubMed
    Score: 0.053
  10. Genotype-targeted local therapy of glioma. Proc Natl Acad Sci U S A. 2018 09 04; 115(36):E8388-E8394.
    View in: PubMed
    Score: 0.050
  11. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017 04 01; 19(4):535-545.
    View in: PubMed
    Score: 0.046
  12. Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. Clin Cancer Res. 2016 Sep 01; 22(17):4452-65.
    View in: PubMed
    Score: 0.043
  13. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell. 2015 Dec 14; 28(6):773-784.
    View in: PubMed
    Score: 0.042
  14. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015 Nov; 5(11):1164-1177.
    View in: PubMed
    Score: 0.041
  15. Proton therapy for low-grade gliomas: Results from a prospective trial. Cancer. 2015 May 15; 121(10):1712-9.
    View in: PubMed
    Score: 0.039
  16. Sporadic hemangioblastomas are characterized by cryptic VHL inactivation. Acta Neuropathol Commun. 2014 Dec 24; 2:167.
    View in: PubMed
    Score: 0.039
  17. Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov. 2014 Nov; 4(11):1299-309.
    View in: PubMed
    Score: 0.038
  18. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res. 2014 Jun 01; 20(11):2898-909.
    View in: PubMed
    Score: 0.037
  19. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol. 2013 Jan; 10(1):14-26.
    View in: PubMed
    Score: 0.034
  20. Prospective, high-throughput molecular profiling of human gliomas. J Neurooncol. 2012 Oct; 110(1):89-98.
    View in: PubMed
    Score: 0.033
  21. Exacerbation of cerebral radiation necrosis by bevacizumab. J Clin Oncol. 2011 Mar 01; 29(7):e159-62.
    View in: PubMed
    Score: 0.030
  22. MSH6 inactivation and emergent temozolomide resistance in human glioblastomas. Clin Neurosurg. 2008; 55:165-71.
    View in: PubMed
    Score: 0.024
  23. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res. 2007 Apr 01; 13(7):2038-45.
    View in: PubMed
    Score: 0.023
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.